Immunotherapy: Cancer immunotherapy and the value of cure

Patient Versus Physician Valuation of Durable Survival Gains: Implications for Value Framework Assessments

(2017) Jason Shafrin et al.   VALUE IN HEALTH

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

(2017) Courtney Davis et al.   BMJ-British Medical Journal

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

(2017) Courtney Davis et al.   BMJ-British Medical Journal

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Medians and Milestones in Describing the Path to Cancer Cures

(2016) Matthew D. Hellmann et al.   JAMA Oncology

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

The Strength of Association Between Surrogate End Points and Survival in Oncology

(2015) Vinay Prasad et al.   JAMA Internal Medicine

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE